View Older Stories View More Recent Stories

Mar 7, 2016 08:00AM AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Mar 7, 2016 08:00AM AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Mar 4, 2016 12:46PM AbbVie (ABBV), J&J (JNJ) Announce FDA Approval of IMBRUVICA as First-Line CLL Treatment
Mar 4, 2016 12:45PM IMBRUVICA® (ibrutinib) Approved by U.S. FDA for the First-line Treatment of Chronic Lymphocytic Leukemia
Mar 2, 2016 08:00AM AbbVie Announces New Dermatology Research from More Than 35 Presentations on HUMIRA® (Adalimumab), Long-Term and Real-World Data at the American Academy of Dermatology 2016 Annual Meeting
Feb 29, 2016 08:05AM AbbVie to Present at Cowen and Company 36th Annual Health Care Conference
Feb 26, 2016 09:35AM AbbVie (ABBV) Announces Positive CHMP Opinion for VIEKIRAX Without Ribavirin in HCV
Feb 26, 2016 09:33AM AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype
Feb 26, 2016 06:42AM AbbVie (ABBV) Announces Receipt of EMA Orphan Drug Designation for Venetoclax as AML Treatment
Feb 26, 2016 06:00AM AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
Feb 23, 2016 10:37AM Notable Analyst Rating Changes 2/23: (ABBV) (TWTR) (NLY) Upgraded; (EVEP) (FCX) (X) Downgraded
Feb 18, 2016 11:05AM AbbVie Declares Quarterly Dividend
Feb 10, 2016 06:57AM AbbVie (ABBV) Announces Second Elagolix Phase 3 Met co-Primary Endpoints in Endometriosis (NBIX)
Feb 10, 2016 06:55AM AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis
Jan 29, 2016 07:49AM Bristol-Myers Squibb (BMY), AbbVie (ABBV) Announce Receipt of Positive CHMP Opinion for Empliciti as Multiple Myeloma Treatment
Jan 29, 2016 07:48AM Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion for Investigational Antibody, Empliciti (elotuzumab), for the Treatment of Multiple Myeloma in Patients Who Have Received at Least One Pri
Jan 29, 2016 07:47AM AbbVie Reports Full-Year 2015 and Fourth-Quarter Financial Results
Jan 28, 2016 07:25AM AbbVie (ABBV) Announces Receipt of FDA Breakthrough Therapy Designation for Venetoclax Combo in Certain AML
Jan 28, 2016 07:23AM AbbVie (ABBV), Neurocrine Bio (NBIX) Initiate Enrollment in Phase 3 Study of Elagolix in Patients with Uterine Fibroids
Jan 28, 2016 06:55AM AbbVie Initiates Enrollment in Phase 3 Clinical Program for Elagolix in Patients with Uterine Fibroids
Jan 28, 2016 12:59AM Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy
Jan 21, 2016 08:31AM AbbVie (ABBV) and MD Anderson Partner on Cancer Immunotherapy
Jan 21, 2016 08:30AM MD Anderson, AbbVie Connect to Advance Cancer Immunotherapy
Jan 20, 2016 08:31AM AbbVie's (ABBV) Venetoclax Combo Granted FDA Breakthrough Therapy Designation for r/r CLL
Jan 20, 2016 08:30AM AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Jan 12, 2016 08:33AM AbbVie (ABBV) Announces Regulatory Acceptance of Venetoclax Apps in Europe, U.S.
Jan 12, 2016 08:30AM U.S. and European Regulators Accept Applications for AbbVie's Venetoclax, the First Potential BCL-2 Inhibitor for Chronic Lymphocytic Leukemia
Jan 11, 2016 07:00AM AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen
Jan 8, 2016 09:01AM AbbVie (ABBV) Commences ABT-494 Phase 3 as RA Treatment
Jan 8, 2016 09:00AM AbbVie Announces the Launch of Robust Phase 3 Clinical Trial Program Evaluating ABT-494, an Investigational Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
Jan 7, 2016 04:20PM AbbVie to Host Fourth-Quarter and Full-Year 2015 Earnings Conference Call
Jan 7, 2016 09:02AM AbbVie (ABBV) Says FDA Gives Priority Review for Supplemental New Drug Application for VIEKIRA PAK
Jan 7, 2016 09:00AM U.S. FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chro
Dec 16, 2015 08:05AM AbbVie to Present at the 34th Annual J.P. Morgan Healthcare Conference
Dec 7, 2015 04:36PM Data from IMBRUVICA Phase 2 RESONATE-17 Presented at ASH 2015; High ORR Noted (JNJ) (ABBV)
Dec 7, 2015 08:38AM AbbVie (ABBV) Announces Significant PFS Data from IMBRUVICA Phase 3 RAY
Dec 7, 2015 08:30AM IMBRUVICA® (Ibrutinib) Phase 3 RAY Data Show Significant Reductions in Disease Progression versus Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma Patients
Dec 7, 2015 07:16AM AbbVie (ABBV) Announces Positive ORR Data from Ibrutinib Combo Phase 2 as FL Treatment
Dec 7, 2015 07:15AM Combination Ibrutinib (IMBRUVICA®) Demonstrates a Strong Response Rate in Treatment-Naive Patients with Follicular Lymphoma
Dec 7, 2015 06:19AM Janssen Announces Phase 3 RESONATETM-2 Met All Efficacy Endpoints
Dec 7, 2015 06:19AM AbbVie (ABBV) Announces Publication of Positive Venetoclax Data as CLL Treatment
Dec 6, 2015 05:30PM Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma
Dec 6, 2015 12:00PM AbbVie Announces New England Journal of Medicine Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia
Dec 6, 2015 11:05AM AbbVie Reports Phase 2 Results of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion
Dec 6, 2015 11:00AM Ibrutinib (IMBRUVICA®) Improves Survival in Treatment-Naive Chronic Lymphocytic Leukemia Patients in the Phase 3 RESONATE™-2 Trial
Dec 4, 2015 08:00AM AbbVie Launches Crohn's & Colitis Scholarship to Support Students Living with Inflammatory Bowel Disease
Dec 2, 2015 08:00AM AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) to Treat Genotype 1 Chronic H
Nov 30, 2015 03:14PM Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies
Nov 16, 2015 09:00AM AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C
Nov 14, 2015 09:01AM AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis
View More Recent Stories View Older Stories